The QualityStocks Daily Thursday, June 13th, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (CETX) +971.43%

QualityStocks (CLCI) +76.67%

NetworkNewsWire (RNWR) +63.46%

The QualityStocks Daily Stock List

Elio Motors, Inc. (ELIO)

The Verge, Zacks, Green Car Reports, OTC Markets, Marketbeat and Green Car Congress reported earlier on Elio Motors, Inc. (ELIO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Elio Motors, Inc. designs, develops, manufactures, and sells automobiles. It concentrates on developing the ultra-high-mileage, low-cost, three-wheel Elio vehicle for mass production in the United States. Elio Motors was founded by car enthusiast Mr. Paul Elio. The Company’s first manufacturing site will be a former General Motors plant in Shreveport, Louisiana. Elio has its corporate office in Phoenix, Arizona.

The three-wheel Elio is engineered to achieve a highway mileage rating of up to 84 mpg. This is while providing the comfort of amenities including power windows, power door locks, air conditioning and cruise control, accompanied by the safety of manifold air-bags and an aerodynamic, enclosed vehicle body. Each Elio comes equipped with a Safety Management System. This includes three airbags, a unibody frame, an Anti-Lock Braking System, and 50 percent larger crush zones than similar vehicles.

Elio is American made. It is engineered to deliver the highest safety standards. Elio gets up to 84 MPG highway due to its inventive design. Gas mileage is determined by how much wind resistance there is on a vehicle. Elio is half the width of a regular car; therefore it gets twice the mileage. The Company’s four ‘must-haves” include excellent MPG (miles per gallon); uncompromised safety; an All-American pedigree; and low price.

In September of 2018, Elio Motors announced that it entered into a memorandum of understanding (MOU) with a Fortune 500 OEM (original equipment manufacturer), to provide the engine foundation as part of a new powertrain for the Elio vehicle. The Company projects that the new powertrain will result in $120 million in research and development (R&D) cost savings.

Elio Motors is working with the engineering team at Roush to develop a new Elio prototype utilizing the OEM powertrain. Roush will integrate the new powertrain into Elio's prototype so as to commence preliminary testing procedures. These testing procedures will prepare the Elio for production.

Elio Motors, Inc. (ELIO), closed Thursday's trading session at $1.85, up 7.56%, on 730 volume with 3 trades. The average volume for the last 3 months is 2,587 and the stock's 52-week low/high is $1.269/$5.15.


Birchcliff Energy Ltd. (BIREF)

Top Stocks News, OilandGas360, Canadian Insider, Energy Now, Simply Wall St, GlobeNewswire, Stockhouse, Trading View, Marketbeat, Stockwatch, Business Insider, and Market Screener reported previously on Birchcliff Energy Ltd. (BIREF), and today we are highlighting Company, here at the QualityStocks Daily Newsletter.

Birchcliff Energy Ltd. explores for, develops, and produces natural gas, crude oil, and natural gas liquids in Western Canada. An intermediate oil and natural gas company, it has operations concentrated within its one core area, The Peace River Arch Of Alberta. Birchcliff has considerable in-house technical expertise and experience on the Peace River Arch. Established in 2004, Birchcliff Energy is based in Calgary, Alberta.

The Company has focused assets in the Peace River Arch Area of Alberta on the Montney/Doig Resource Play. It essentially has a 100 percent working interest (WI); 99 percent of production is operated. Birchcliff has a large, contiguous undeveloped land base with an average 89 percent WI.

Birchcliff Energy has significant control of infrastructure. This includes the 100 percent owned and operated 340 MMcf/d Pouce Coupe Gas Plant (PC Gas Plant). In addition, the Company has a low decline production base (estimated 20 percent in 2019), and a top tier cost structure driving peer leading profitability.

Furthermore, Birchcliff Energy has a 2P reserve life index (RLI) of approximately 35.6 years as at December 31, 2018. The Company had 385 (380.6 net) Montney/Doig horizontal wells drilled as at December 31, 2018. Moreover, Birchcliff had 6,365.8 net future potential Montney/Doig horizontal drilling locations as at December 31, 2018.

Birchcliff Energy’s key strategic attributes include 18 gross (15.1 net) Montney sections contiguous to existing BIR infrastructure. There is the potential for 4 Montney intervals (Montney D1, D2, C, Basal Doig/Upper Montney). Birchcliff drilled a 6 well pad in Q1 2019. It is to be completed and brought on production in Q3 2019. The strategic land acquisition provides additional liquids rich drilling inventory to fill the Pouce Coupe Gas Plant.

The acquisition included roughly 700 boe/d of legacy production. The acquisition was evaluated chiefly on land acquisition metrics and future drilling opportunities. The construction of the 340 MMcf/d PC Gas Plant is in six separate phases and is on time and on budget.

Birchcliff Energy’s production averaged 74,884 boe/d in Q1 2019. This represents a 2 percent decrease from 76,323 boe/d in Q1 2018. The decrease was mainly attributable to the timing of bringing new production on-stream and natural production declines, partially offset by incremental production from new horizontal oil and natural gas wells brought on production. For Q1 2019, the Company drilled 13 (13.0 net) wells and brought 12 (12.0 net) wells on production.

Birchcliff Energy Ltd. (BIREF), closed Thursday's trading session at $2.0884, up 0.02%, on 96,206 volume with 97 trades. The average volume for the last 3 months is 29,170 and the stock's 52-week low/high is $2.099/$9.00.


Hut 8 Mining Corp. (HUTMF)

Invest Tribune, Stockwatch, Market Screener, Wallet Investor, 4-Traders, Investorx, YCharts, Investor Ideas, Small Cap Power, OTC Markets, Stockhouse, Cryptocredits, CoinNews Telegraph, InvestorsHub, Midas Letter, Trading View, MarketWatch, Seeking Alpha, Morningstar, and Barchart reported previously on Hut 8 Mining Corp. (HUTMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Hut 8 Mining Corp. is one of the world's largest publicly traded cryptocurrency mining companies by operating capacity and market capitalization. It has industrial scale bitcoin mining operations in Canada. Hut 8 provides investors with direct exposure to bitcoin, without the technical complexity or constraints of buying the underlying cryptocurrency. As a result, investors avoid the need to create online wallets, wire money offshore, and safely store their bitcoin. Hut 8 Mining’s registered office is in Vancouver, British Columbia.

Hut 8 Mining has an exclusive North American partnership with the Bitfury Group Limited, inclusive of Bitfury Holding BV, (Bitfury), one of the world's top full-service hardware and software blockchain technology companies. The Bitfury Group’s expertise ensures successful, secure, and cost-effective connectivity to the blockchain. Bitfury provides turn-key services to install, service, as well as maintain BlockBox datacenters.

Hut 8 Mining has an exclusive option for the future acquisition and development of datacenters and a broad and proprietary mix of hardware, software, installation and operational services in North America. Concerning secured, low cost electricity, the Company is operating 95.2 MW in Drumheller and Medicine Hat, Alberta, with access to additional power in Canada.

In Medicine Hat, Alberta, 56 BlockBox datacenters are operating at a maximum capacity of 62.7 MW and 504 PH/s at full load. In addition, in Drumheller, Alberta, 29 BlockBox datacenters are operating at a maximum capacity of 32.5 MW producing 280 PH/s at full load.

Hut 8 Mining expanded its operations from 7 to 85 BlockBox data centers through 2018. The Company also increased PH/s capacity by 1,300 percent from 56 to 784 PH/s. Furthermore, Hut 8 entered into a definitive agreement with the City of Medicine Hat for the supply of 42 MW and 21 MW of additional off-grid energy. Hut 8 also completed its flagship site in the City of Medicine Hat. This represents an increase of 63 MW of operating capacity for an aggregate of 95.2 MW in operation at year end.

Recently, Hut 8 Mining announced its financial results for Q1 ended March 31, 2019. Q1-2019 highlights include Revenue of $12.1 million and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of negative $1.3 million for Q1-2019. Moreover, 2,405 bitcoin was mined in Q1-2019.

Hut 8 Mining recognized negative $1.3 million in Adjusted EBITDA, the first quarter of negative Adjusted EBITDA operations for the Company. A net loss was recorded for the quarter of $6,065,495. Both losses were mainly because of bitcoin prices remaining at roughly 52-week lows during Q1-2019, hash rates increasing, and volatile natural gas prices that all negatively impacted operations for the quarter.

Hut 8 Mining Corp. (HUTMF), closed Thursday's trading session at $1.7118, up 3.12%, on 21,850 volume with 21 trades. The average volume for the last 3 months is 25,438 and the stock's 52-week low/high is $0.599/$2.85.


Silex Systems Limited (SILXY)

Stockaholics, Penny Stock Hub, Speculating Stocks, Proactive Investors, Wallet Investor, OTC Markets, OTC.Watch,, and 4-Traders reported beforehand on Silex Systems Limited (SILXY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Silex Systems Limited is a high-technology company based in Australia. It focuses on the delivery of the innovative and disruptive SILEX Laser Enrichment Technology as the next generation technology for the worldwide uranium enrichment industry. The Company invented and initially developed the ‘SILEX’ laser-based uranium enrichment technology in Sydney during the 1990’s. Silex Systems lists on the OTC Markets Group’s OTCQX.

The ‘SILEX’ laser-based uranium enrichment technology was licensed exclusively in 2006 to GE-Hitachi Global Laser Enrichment LLC (GLE). GLE is a business venture presently consisting of GE (51 percent), Hitachi (25 percent) and Cameco (24 percent). Silex and GLE jointly continue to commercialize the technology for potential deployment in the United States. Silex Systems scientists Dr. Michael Goldsworthy and Dr. Horst Struve invented the SILEX technology in the mid 1990’s at Lucas Heights, Sydney.

In essence, the SILEX technology is an inventive laser-based process. It has the potential to economically separate uranium isotopes as well as commercially valuable isotopes of a number of other elements. Its advantages over other uranium enrichment processes include inherently higher efficiency resulting in lower costs. Advantages also include a smaller environmental footprint than centrifuge and diffusion plants. Furthermore, it has greater flexibility in producing advanced fuels for next generation small modular reactors (SMR's). The SILEX technology is also expected to have the lowest capital costs of all enrichment technologies.

Silex subsidiary Translucent, Inc. developed a novel set of semiconductor materials known as ‘crystalline Rare Earth Oxides’ (cREO™). These are for application to the manufacturing of next generation semiconductor devices used in wireless communications, power electronics and other advanced semiconductor industries.

Silex Systems recently provided an update on its recent activities. Silex is working towards finalization of a binding purchase agreement for the restructure of SILEX technology licensee GE-Hitachi Global Laser Enrichment LLC (GLE). This follows the signing of a Term Sheet on February 5, 2019 that provides the key terms for a proposed joint purchase by Silex and Cameco of GE-Hitachi’s (GEH) 76 percent interest in GLE. Subject to obtaining U.S. Government approvals, the proposed restructure of GLE would result in Silex Systems acquiring a 51 percent interest, and Cameco increasing its interest in GLE from 24 percent to 49 percent.

Regarding the Translucent cREO™ technology and IQE, IQE Plc (LON: IQE), who acquired Translucent’s unique cREO™ semiconductor materials technology in March of 2018, disclosed on March 20, 2019 in the commentary to its full year results that positive progress continues to be made in the commercialization of cREO™ for application in many of its key target markets. A perpetual royalty of between 3 percent and 6 percent will be payable to Translucent on the sale of any IQE products globally that use the cREO™ technology, with minimum annual royalties due to start being paid in FY2020 for the first 6 years.

Silex Systems Limited (SILXY), closed Thursday's trading session at $1.40, up 8.53%, on 225 volume with 2 trades. The average volume for the last 3 months is 78 and the stock's 52-week low/high is $0.56/$1.572.


ES Bancshares, Inc. (ESBS)

All Stocks Today, Stock Scores, Whale Wisdom, Financial Buzz, Stockwatch, Simply Wall St, Dividend Investor, Investors Hangout, GlobeNewswire, Stockhouse, and Wallet Investor reported previously on ES Bancshares, Inc. (HGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ES Bancshares, Inc. is the holding company for Empire State Bank. Through subsidiary Empire State Bank, the Company provides diverse commercial banking products and services in New York. In June of 2004, Empire State Bank commenced operations as a full-service, community-oriented bank, with the aim of providing customers with high quality personalized banking services, unique financial products and competitive rates. ES Bancshares is headquartered in Newburgh, New York.

Empire State Bank offers a complete line of checking, deposit and loan products. These products are tailored to meet the specific needs of the customers and businesses it serves in the Hudson Valley Region, New York Metro Area, and beyond.

The Bank’s locations include the Newburgh Banking Center & Loan Center in Newburgh, New York, and the New Dorp Banking Center & Loan Center in Staten Island, New York. Locations also include the Victory Boulevard Banking Center & Loan Center in Staten Island, and the Victory Boulevard Loan Center in Staten Island. In addition, locations include the 3rd Ave. Banking Center & Loan Center in Brooklyn, New York, as well as the 18th Ave. Banking Center & Loan Center also in Brooklyn.

Empire State Bank offers various deposit products. These include personal and business checking and money market accounts, personal and business savings accounts, individual retirement accounts, and certificates of deposits. The Bank also provides SBA loans and lines of credit, commercial term loans, secured and commercial letters of credit, and commercial real estate loans.

Empire State Bank also offers debit card, direct deposit, automatic loan payment, automatic loan payment and transfer, combined statement, wire transfer, remote deposit, merchant card, cash and escrow management, night depository, and online and telephone banking services. Moreover, the Bank invests in mortgage-backed and other securities.

Last month, ES Bancshares announced a $171,000 increase in Net Income to $414,000, or $0.10 per common share for the quarter ended March 31, 2019, versus $243,000, or $0.06 per common share for the quarter ended March 31, 2018. The improvement was mainly driven by a $542,000, or 23.1 percent increase in Net Interest Income, and a $220,000 decrease in the provision for Loan Losses, offset by a $497,000 increase in Operating Expenses. The increase in Net Interest Income was primarily because of an $80.0 million or 28.7 percent increase in Loans Receivable to $359.1 million as of March 31, 2019 versus $279.1 million as of March 31, 2018.

ES Bancshares, Inc. (ESBS), closed Thursday's trading session at $4.25, up 11.55%, on 3,178 volume with 2 trades. The average volume for the last 3 months is 781 and the stock's 52-week low/high is $3.40/$5.17.


Blockchain Industries, Inc. (BCII)

BlockchainStocks, Dividend Investor, 4-Traders, Trading View, Last10k, OTC Markets, Stockopedia, Stockhouse, Wallet Investor, Wallmine, Whale Wisdom, Simply Wall St, and MarketWatch reported earlier on Blockchain Industries, Inc. (BCII), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Blockchain Industries, Inc. is a merchant bank focused on the global blockchain and cryptocurrency sectors. It consists of a Blockchain Technology Advisory, an Investment Management arm, and a Global Conference Series (Blockchain Unbound) connecting entrepreneurs and investors. The Company previously went by the name Omni Global Technologies, Inc. It changed its name to Blockchain Industries, Inc. in November of 2017. Blockchain Industries is headquartered in Santa Monica, California.

The Company’s corporate mission is to make Blockchain Technology accessible, transparent and compliant. Blockchain Industries concentrates on long-term results - in innovation that can help governments streamline their processes, rebuild struggling economies, transform legislative practices, revolutionize healthcare and education, and ultimately better humanity.

Blockchain Industries offers early access to coveted protocols and token issuances, and considerable technical competence, an extensive industry network, and a recognized global brand. In addition, it offers top-tier experiences in finance and operations with an emphasis on compliance and risk management.

The Company’s intention is to offer investment management for blockchain-related assets; and blockchain advisory services. This includes architecting token structure and issuance, crypto-economic design, technology/engineering, consulting, generating whitepapers, software development, and marketing. Additionally, its intention is to invest in, partner with, or acquire media streams, news outlets, or other content distribution methods centered on the marketing of blockchain technologies and Digital Asset economies; partner with educational institutions to train blockchain developers; and set up cryptocurrency mining facilities.

This past March, GoChain announced it has partnered with IriSafe, Inc. and Blockchain Industries to develop blockchain-based identity management solutions. IriSafe is a Singapore-based joint venture (JV) between IriTech and Blockchain Industries. With guidance from Blockchain Industries, GoChain and IriSafe entered a binding joint development agreement.

GoChain will take advantage of IriTech's biometrics hardware and software development kits in collaboration with IriSafe to provide the world's first blockchain identity management solutions using ultra-secure, government-tested and certified iris-scanning technology. These solutions will be constructed on GoChain's best-performing public web3-based network, giving users quicker transaction speeds and enterprise-level support that are not available with traditional identity management solutions.


Blockchain Industries, Inc. (BCII), closed Thursday's trading session at $2.15, down 2.27%, on 412 volume with 4 trades. The average volume for the last 3 months is 471 and the stock's 52-week low/high is $1.03/$6.50.


Cosmos Holdings, Inc. (COSM)

Proactive Investors, Real Investment Advice, Tech Know Bits, Stockwatch, Stockopedia, and Stockhouse reported previously on Cosmos Holdings, Inc. (COSM), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Cosmos Holdings, Inc. is a global pharmaceutical company headquartered in Chicago, Illinois. The Company specializes in, by way of its subsidiaries, the wholesale of pharmaceutical products throughout Europe. It provides its products to wholesale drug distributors, and wholesalers and retail healthcare providers. Cosmos Holdings lists on the OTC Markets’ OTCQB.

The Company distributes branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical via its trans-European network of more than 160 pharmaceutical wholesale clients and vendors and roughly 400 independent retail pharmacies that extends to 16 countries. These include Germany, the United Kingdom, France, Italy, Poland, the Netherlands, Greece, Hungary, Denmark, Ireland, and Croatia.

Regarding its new nutraceutical brand, Cosmos Holdings released the design and packaging of its first set of dietary supplements on April 19, 2018. These premium supplements feature a sleek design and packaging along with best in class formulation. The first lines of products include Herbal syrups with natural ingredients from Greece, Collagen 24k, Organic Aloe Vera, Hyaluronic, Male & Female Multivitamins, and more.

Specific areas of Company Management's focus include Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Cannabis derived products, and Local & Direct to Pharmacy Wholesale.

Cosmos Holdings’ subsidiaries include Sky Pharm SA. Sky Pharm is based in Thessaloniki, Greece. Sky Pharm trades the excess amounts of approximately 500 medicines that can be exported within the European Union (EU) countries. Another subsidiary is Decahedron Ltd. Decahedron is a pharmaceutical wholesaler incorporated in the United Kingdom (UK) in August of 2011. A third subsidiary is Cosmofarm Pharmaceuticals. Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. Cosmos has entered the nutraceutical market with its own premium brand of food supplements - Sky Premium Life.

Recently, Cosmos Holdings announced its full-year 2018 financial results for the year ended December 31, 2018. 2018 highlights include Revenue improving 23.6 percent to $37 million from $30 million in 2017. Gross Profit increased 23.1 percent to $2.4 million from $1.96 million in 2017. Operating Expenses decreased by 46.7 percent year over year.

Cosmos Holdings, Inc. (COSM), closed Thursday's trading session at $3.70, up 4.52%, on 1,650 volume with 16 trades. The average volume for the last 3 months is 689 and the stock's 52-week low/high is $2.0295/$9.00.


Molori Energy, Inc. (MOLOF)

Awesome Stock Picks, MarketWatch, 4-Traders, Zacks, OTC Markets, Stockhouse, Streetwise Reports, InvestorsHub, MarketWatch, Seeking Alpha, and Proactive Investors reported previously on Molori Energy, Inc. (MOLOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Molori Energy, Inc. has present operations in the Texas Panhandle West Field. The Company’s operating team based in Borger, Texas has wide-ranging experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through focusing on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions.

An oil and gas production business, Molori Energy is based in Vancouver, British Columbia. The Company formerly went by the name Taipan Resources, Inc. In January 2017, it changed its corporate name to Molori Energy, Inc.

The Company’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to generate steady cash flows. Molori owns a 25 percent Working Interest (WI) in certain leases situated in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC.

Molori Energy has 165 producing (PDP) wells and an inventory of roughly 202 non-producing wells (PDNP) for a total of 367 wells. It is working to RTP (Return to Production) the PDNP wells through performing simple re-works or re-completions.

In 2018, Molori Energy provided an update pertaining to its operations in Moore County and Hutchinson County, Texas. On May 7, 2018, it announced the first of two Letters of Intent (LOIs) to acquire a 100 percent Working Interest (WI) in about 30,000 acres with access to the Red Cave and other formations. The acreage, in Moore, Potter, Carson and Hutchinson counties, is HBP (Held By Production), and includes 8 currently-producing wells.

On May 22, 2018, Molori Energy announced the second LOI for the purchase of a 100 percent WI in an additional 5,100 acres in the Red Cave formation. An 81 acre tract included within the proposed purchase is of significant interest because it adjoins property owned by Adams Affiliates, Inc., (Tulsa, Oklahoma), who successfully drilled greater than 50 Red Cave wells in the past three years. The 81 acre tract also offers 18 drill-ready locations. This 5100 acres is also HBP.

Molori Energy, Inc. (MOLOF), closed Thursday's trading session at $0.22, up 14.42%, on 30 volume with 11 trades. The average volume for the last 3 months is 18,911 and the stock's 52-week low/high is $0.002/$0.24.


GGX Gold Corp. (GGXXF)

Jet Life Penny Stocks, Junior Mining Network, The Street, Penny Stock Hub, Wall Street Pennies, Stockwatch, Wallet Investor, 4-Traders, Barchart, Resource World, Proactive Investors, Dividend Investor, Mining Capital, MarketWatch, Wallmine, Investment Pitch, OTC Markets, YCharts, Investors Hangout, GuruFocus and Stockhouse reported beforehand on GGX Gold Corp. (GGXXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GGX Gold Corp. is a gold exploration company listed on the OTCQB. It is rejuvenating an historic British Columbia gold camp with new discoveries. The Company previously went by the name Revolver Resources, Inc. It changed its name to GGX Gold Corp. in October 2016. GGX Gold has its corporate headquarters in Vancouver, British Columbia.

The Company’s Gold Drop project encompasses an area of greater than 5,600 hectares. The Gold Drop Project is positioned 40 km from Grand Forks, British Columbia on geologically prospective ground in the well-mineralized Greenwood Mining District. GGX Gold has discovered two new significant gold bearing vein structures - the C.O.D. and Everest veins. Also, GGX owns nine percent of a private syndicate centered on project generation within the Golden Triangle.

Drilling and trenching during the 2017 exploration season and the 2018 season have led to the discovery of significant gold bearing structures. These structures are predominant throughout the property. Gold Drop’s historical production totals 7572 tonnes at an average grade of 5.2 g/t Au and 93.4 g/t Ag. The 7572 tonnes was mined from three main veins - Amandy, North Star and Gold Drop.

Recently, GGX Gold summarized highlights of the 2018 exploration season on the Gold Drop Property in Southern British Columbia. The program concentrated on the C.O.D vein in the Gold Drop Southwest Zone. During the drilling program GGX also conducted mechanical trenching on manifold targets.

The Company completed 71 diamond drill holes on the C.O.D vein. High-grade intersections include 107.5 g/t gold and 880 g/t silver over 6.90 meters core length and 129 g/t gold and 1,154 g/t silver over 7.28 meter core length. GGX extended the C.O.D vein 160 m to the southwest via drilling.

The Company completed 19 diamond drill holes on the Everest vein. In addition, it discovered the southern extension of the Gold Drop vein via mechanical trenching. It also completed 30 m of trenching on the Silent Friend Vein. GGX completed a thorough trenching program in the C.O.D North area of the property.

Recently, GGX Gold announced it requested tellurium re-analysis of select drill core samples from the Fall 2018 diamond drill program at the Gold Drop Property in southern British Columbia. The Fall 2018 drill program was conducted at the C.O.D. Vein in the Gold Drop Southwest Zone. Numerous drill core samples from drill holes COD18-67 and COD18-70 surpassed the upper 500 grams per tonne (g/t) analytical limit for tellurium. The samples returned high grade values for gold and silver. These samples will be re-analyzed to ascertain tellurium grades.

GGX Gold Corp. (GGXXF), closed Thursday's trading session at $0.0529, up 24.18%, on 3,000 volume with 3 trades. The average volume for the last 3 months is 5,205 and the stock's 52-week low/high is $0.0363/$0.10.


PharmaCyte Biotech, Inc. (PMCB)

SmallCapNetwork, MyBestStockAlerts, Wall Street Corner, Penny Stock General, PennyStockInformer, Cannabis Financial Network News, BUYINS.NET, Fast Money Alerts, Penny Stock Beats, The Stock Psycho, Stock Shock and Awe, OTC Journal, Penny Stock Laboratory, Stock Market Media Group, InvestorPlace, Goldman Small Cap Research, Damn Good Penny Picks, Penny Picks, and Darth Trader reported earlier on PharmaCyte Biotech, Inc. (PMCB), and today choose to report on the Company, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. concentrates on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This unique and patented technology is being used as a platform upon which treatments for many kinds of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology Company and OTCQB-listed, PharmaCyte Biotech has its corporate office in Silver Spring, Maryland.
The Company is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other kinds of solid cancerous tumors.  PharmaCyte’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. 

The capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. The live-cell encapsulation technology that the Company employs is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. It encapsulates living cells, not drugs. PharmaCyte Biotech is advancing its new treatment for pancreatic cancer into the clinic in the United States, with study sites in Australia and Europe.

Furthermore, the Company is developing treatments for cancer built upon chemical constituents of the cannabis  plant, called cannabinoids. PharmaCyte is studying ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects typically associated with cancer treatments.

Recently, PharmaCyte Biotech announced that its partner, Austrianova, successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The cells are currently growing and dividing inside the Cell-in-a-Box® capsules.

PharmaCyte Biotech’s Chief Executive Officer, Mr. Kenneth L. Waggoner, said, “We are now in the process of monitoring the growth and division of the live cells as they spend more time in a ‘nutrient bath.’ This will allow the cells to continue to grow and divide and then completely fill the capsules. Once the capsules are completely full of live cells, they will be placed into syringes and frozen. Austrianova will then commence testing the capsules in the frozen syringes to finalize PharmaCyte’s clinical trial material.”

PharmaCyte Biotech, Inc. (PMCB), closed Thursday's trading session at $0.0387, up 0.58%, on 549,611 volume with 36 trades. The average volume for the last 3 months is 1,648,214 and the stock's 52-week low/high is $0.035/$0.0885.


Cuentas, Inc. (CUEN)

InvestorsHub, AIStockFinder, Wallet Investor, MarketWatch, GuruFocus, Barchart, The Street, Investors Hangout, Market Screener, Street Insider, and PR Newswire reported on Cuentas, Inc. (CUEN),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Cuentas, Inc. is a Financial Technology (FinTech) service provider listed on the OTC Markets’ OTCQB. The Company provides mobile banking, online banking, prepaid debit and digital content services to unbanked, underbanked and underserved communities. It utilizes technical innovation together with existing and emerging technologies to provide accessible, efficient and reliable mobile, new-era and traditional financial services to consumers. Cuentas has its corporate headquarters in Miami, Florida.

The Company’s business units are Cuentas Mobile and Cuentas Pinless. It offers mobile with its STI Mobile. With STI Mobile there are no commitments and flat rates. STI Mobile is good for the USA and more than 100 international destinations. Cuentas Mobile also offers its new data services plan and features high speed and reliable internet. It supports 3G/4G/LTE networks. Cuentas Pinless offers TEL3 for making international calls. With TEL3, one can see their call history with the online account manager, call faster with the Speed Dial feature, and register their phone to make pinless calls. TEL3 offers low rates and a customer can save by getting recharge coupons directly on their phone, earning up to 5 percent of their total spending as reward points (free minutes). They will also get $10 worth of free minutes for every friend they refer.

In November 2018, Cuentas announced that its wholly-owned subsidiary Limecom, which specializes in wholesale international telecommunications services provided through Voice over Internet Protocol (VoIP), executed a $4 million, three-year, factoring facility with AEC Yield Capital, LLC, an affiliate of Advanced Energy Capital, LLC (AEC). Limecom has interconnections with greater than 100 Carriers globally and has provided more than 2 billion minutes of voice traffic.

Limecom produced revenue of more than $100M in fiscal 2017. In fiscal 2018, Cuentas' Income Statement will reflect 100 percent of the revenue of Limecom. AEC will provide an initial availability of $4 million for periodical purchasing of Limecom invoices. This facility will permit Limecom to grow its business unit considerably. Cuentas, which provides its mobile banking customers with Telecommunications Long Distance Rewards, will be using Limecom's International Network Legacy for these rewards.

Recently, Cuentas announced that it rescinded its Stock Purchase Agreement with Limecom that will further decrease its debt by more than $3.3 Million. The Company’s debt reduction of $3.3 Million includes monies owed to Heritage Ventures Limited and employees of Limecom.

According to the Amendment to Stock Purchase Agreement executed January 29, 2019, a scheduled payment of $2 million to Heritage Ventures limited for the Stock Purchase Agreement pertaining to Limecom was cancelled. Pending loans to Heritage for $750,000 were exchanged for 90,000 shares of Cuentas. In addition, a number of executives, employees and contractors of Limecom converted $572,448 of compensation for 18,576 Cuentas shares, accepting a Company valuation of $50 million.

Cuentas, Inc. (CUEN), closed Thursday's trading session at $1.20, up 41.18%, on 10,605 volume with 53 trades. The average volume for the last 3 months is 1,242 and the stock's 52-week low/high is $0.535/$12.30.


Provectus Biopharmaceuticals, Inc. (PVCT)

Top Stock Analysts,  Club Penny Stocks Network, The Street, Streetwise Reports, All Penny Stocks, Stock News Now, Wise Alerts, plrinvest, Investors Underground, Real Pennies, PennyStocks24, Top Penny Stock Movers, Street Insider, Street Authority Daily, and The Microcap News reported previously on Provectus Biopharmaceuticals, Inc. (PVCT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, Provectus Biopharmaceuticals, Inc. is a clinical-stage oncology and dermatology Biopharmaceutical Company. It is developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. The Company`s investigational oncology drug is PV-10.  PV-10 is an oncolytic immunotherapy enrolling patients in Phase 3 clinical trials for metastatic melanoma.  Provectus Biopharmaceuticals has its head office in Knoxville, Tennessee.

PV-10 is an ablative immunotherapy under investigation in solid tumor cancers. PV-10 is a 10 percent solution of small molecule and halogenated xanthene Rose Bengal. It undergoes administration through direct injection into solid tumor cancers, including melanoma, liver, and breast. It is not designed to rely on a single pathway, receptor or antigen to work. There is no known resistance.

The intention of PV-10 is to kill only diseased cells upon injection into tumors. Provectus Biopharmaceuticals has received orphan drug designations from the Food and Drug Administration (FDA) for its melanoma and hepatocellular carcinoma indications. The Company completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

PH-10 is a topical investigational drug for dermatology and is a topical hydrogel formulation. It yields selective delivery of rose bengal disodium to epithelial tissues. Regarding PH-10 for psoriasis and atopic dermatitis, a mechanism of action study is underway to measure the clinical and cellular response to PH-10's active investigational agent. A total of 226 subjects have been treated with PH-10 in Phase 1 or Phase 2 Clinical Trials.

Provectus Biopharmaceuticals announced this past November that it was granted orphan drug designation (ODD) by the FDA for small molecule oncolytic immunotherapy PV-10 for the treatment of neuroblastoma. This is a non-Central Nervous System (CNS) pediatric solid tumor. Intratumoral injection of PV-10 can yield immunogenic cell death (ICD) in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells. ODD status was earlier granted to PV-10 for the treatments of metastatic melanoma in 2007 and hepatocellular carcinoma (HCC) in 2013.

Recently, Provectus Biopharmaceuticals announced that orphan drug designation (ODD) status was granted by the FDA to small molecule oncolytic immunotherapy PV-10 for the treatment of ocular melanoma (to include all melanoma disease affecting the eye and orbit). The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect less than 200,000 people in the United States. ODD status qualifies companies for certain benefits. These benefits include seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, as well as waiver of certain administrative fees.

Provectus Biopharmaceuticals and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) also recently announced that OncoTargets and Therapy (OTT) published preclinical results from in vitro and animal tumor model studies on PV-10 for the treatment of neuroblastoma. POETIC is a group of 10 top-tier academic medical centers developing new pediatric cancer therapies.

The work was led by Dr. Aru Narendran and his team at the University of Calgary’s POETIC Preclinical and Drug Discovery Laboratory. Prior preclinical and clinical studies by other researchers have shown that intratumoral injection of PV-10 can yield immunogenic cell death in adult solid tumors and stimulate tumor-specific reactivity in circulating T cells.

According to the POETIC authors, “Our studies provide preclinical proof-of-concept data on the efficacy of PV-10 in neuroblastoma. Mechanistically, we have found that PV-10 acts by disrupting lysosomes, inducing cell cycle changes and initiating cell death by apoptosis. We have also identified several commonly used treatments with which PV-10 shows synergistic anti-tumor activity. Furthermore, we have validated the efficacy of PV-10 in vivo, using neuroblastoma xenograft mouse experiments.”

Provectus Biopharmaceuticals, Inc. (PVCT), closed Thursday's trading session at $0.0489, up 1.88%, on 59,945 volume with 11 trades. The average volume for the last 3 months is 215,632 and the stock's 52-week low/high is $0.011/$0.078.


Flexpoint Sensor Systems, Inc. (FLXT)

Tip Ranks, Business Insider, The Street, Stockhouse, Simply Wall St, Investopedia, Investing, Research and Markets, MarketWatch, Investors Hub, Uptick Newswire, Super Stock Screener, Equity Clock, Marketbeat, and Investor Place reported earlier on Flexpoint Sensor Systems, Inc. (FLXT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flexpoint Sensor Systems, Inc. is a technology company specializing in developing products that feature its patented Bend Sensor® and associated technology. The Bend Sensor's single-layer, thin film construction reduces expenses and mechanical bulk. It does so while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint Sensor Systems is based in Draper, Utah and the Company lists on the OTC Markets.

The Company produces the Bend Sensor® for manifold applications, encompassing numerous markets. These markets include automotive and transportation, wearables, medical, industrial controls, consumer products, and toys/gaming. Flexpoint offers Consulting, Design, Development, and Manufacturing related to the adoption of the Bend Sensor® technology.

The Bend Sensor® product comprises a coated substrate, such as plastic, that changes in electrical conductivity as it is bent. Electronic systems connect to the sensor and measure with fine detail the amount of bending or movement that takes place. The single layer design of the Bend Sensor® eliminates many of the problems associated with conventional sensors. This includes dust, dirt, liquids, as well as heat and pressure effects.

Since early in 2017, Flexpoint Sensor Systems and CaptoGlove® started a strategic, collaborative relationship to deliver unique, integrated virtual reality/augmented reality (VR/AR) systems driven by Bend Sensors® to mass markets. Flexpoint continues its wide-ranging success in the Virtual Reality/Augmented Reality (VR/AR) market for Glove-Based Systems.

In June 2018, Flexpoint Sensor Systems announced two significant development opportunities. The opportunities involve the implementation of two of the Company’s Bend Sensor® technologies for vehicles, and the development of its Bend® Sensor technology and its testing and proof of concept for tracking and monitoring the use of opioids.

Recently, Flexpoint Sensor Systems announced that it continues to receive production Purchase Orders from award-winning client/partners, including South Korea-based Neofect.  This relationship, originally established in 2015/2016, brought to market smart, inventive, medical glove-based technologies, featuring the Flexpoint Bend Sensor®. Neofect produces the RAPAEL Smart Glove, which is a 2018 CES Innovation award winner.

Mr. Paul Sexauer, Flexpoint Sensor Systems’ Vice President Sales and Marketing, said, “This is the type of client relationship we look to establish, nurture and grow. We are pleased to see the success of Neofect as they have become a part of our growing client/partner base, and we’re honored to have the Bend Sensor® designed into these innovative technologies. The glove-based wearables (medical and VR/AR) market continues to be very exciting for us and one where we are clearly differentiated.”   

Flexpoint Sensor Systems, Inc. (FLXT), closed Thursday's trading session at $0.0724, up 20.67%, on 2,591,428 volume with 95 trades. The average volume for the last 3 months is 59,035 and the stock's 52-week low/high is $0.0295/$0.09.


Pharma-Bio Serv, Inc. (PBSV)

Zacks, Market Screener, Marketbeat, Barchart, Stockopedia, Dividend Investor, Business Wire, Capital Cube, Stockhouse, Morningstar, Marketwired, Wallet Investor, last 10k, YCharts, GuruFocus, MarketWatch, and InvestorsHub reported previously on Pharma-Bio Serv, Inc. (PBSV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter. 

Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. The Company’s primary business is Food and Drug Administration (FDA) and other global regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Pharma-Bio Serv is based in Dorado, Puerto Rico. The Company also has operations in the United States, Ireland, and Spain.

Pharma-Bio Serv supports its clients through the product lifecycle. This includes research and development  (R&D)  Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Additionally, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support. Moreover, its services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts. 

Pharma-Bio Serv’s divisions include Scienza Labs, the above-mentioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

Recently, Pharma-Bio Serv announced that Net Revenues from Continuing Operations for the year ended October 2018 were $17.8 million. This represents an increase of $4.5 million, or 34 percent, versus last year. Net Income for the year ended October 31, 2018 was roughly $1.3 million, an increase in Net Earnings of $2.7 million, versus the year prior.

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "Based on a corporate strategy to refocus the Company on consulting services, we sold substantially all of our laboratory business and discontinued our efforts to pursue opportunities that were not considered strategic to the Company. We believe that consulting services, which have been our core business, will provide the maximum added-value to our clients and shareholders. We are also pleased with the financial results of the Company to date and were delighted to provide a dividend to our loyal shareholders."

Pharma-Bio Serv, Inc. (PBSV), closed Thursday's trading session at $0.85, up 1.49%, on 1,200 volume with 2 trades. The average volume for the last 3 months is 1,598 and the stock's 52-week low/high is $0.432/$1.25.


The QualityStocks Company Corner

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings (CSE: TCAN) (FSE: TH8), through execution of a nonbinding letter of intent to acquire the business and assets of Lyfted Farms Inc. of Modesto, California, is showing continued search for synergies and opportunities in the strategic move. To view the full article, visit:

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) brings together a rapidly growing portfolio of cannabis and hemp-related brands and services, with a closed-loop ecosystem approach rooted squarely in the company’s ownership of a 196,000-square-foot, vertically integrated facility in California. The company has developed a two-year, four-phase plan aimed at developing proprietary brands and creating a self-contained ecosystem that ensures reliability, consistency, quality and scale.


TransCanna’s cannabis facility in Modesto, California, is strategically located less than a three-hour drive from the majority of all major cities in the state. The tri-level building provides internal control of everything needed for the seed-to-sale cycle, from growing and manufacturing to extraction, bottling, transportation and distribution. The facility, which recently went through an US$8 million renovation, is upgraded with a premium quality HVAC system and highly insulated roof to help reduce power costs, which already are some of the lowest in California.

The company has set 2020 goal for implementation of its full-service software platform, 420 Global, which will interact with every aspect of production flow, business development and the sales process.

Growing Portfolio

Acquisitions slated to be completed in June include Goodfellas Group LLC, a full-service advertising and marketing agency for the U.S. cannabis and hemp industries. Under the deal, TransCanna will also be acquiring Daily Cannabis Goods, a pre-rolled brand with nominal start-up costs and superior SKU velocity with cannabis products available at more than 30 dispensaries throughout California.

On Deck

The company has moved to acquire organic hemp-infused CBD coconut oil Biovelle ( Biovelle is non-GMO, vegan and gluten free, with coconut sourced from plantations in the Philippines and American grown hemp from farms in Colorado.

TransCanna has also moved to further secure a growing foothold in cannabis edibles via a non-binding letter of intent with Persuasion Brewing Co., located near the company’s flagship facility in Modesto. The goal is to establish a Persuasion Brewing division at the main facility, which will produce a variety of different CBD infusion non-alcoholic beers.

Similarly, the company has recently executed a non-binding LOI with SolDaze (Tres Ojos Naturals, LLC) to gobble up the branding asset package of this California manufacturer of cannabis-infused fruit snacks (


TransCanna’s management team consists of seasoned agriculture and consumer goods-oriented veterans.

Director, CEO and Chairman James Pakulis has 30 years of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He has been on the front lines of the California cannabis industry for nearly a decade. He was CEO and chairman in 2010 of General Cannabis, Inc., which wholly owned the popular Weedmaps brand. Pakulis oversaw the growth of General Cannabis from pre-embryonic stages to over $16 million in revenue in less than two years, reaching a market cap of approximately $480 million.

Director and President Arni Johannson brings over 30 years of investing experience in the Canadian capital markets. He has built and or funded over 50 startups from around the world. He is president of Canadian Nexus Ventures and has been instrumental in providing guidance to pre- and post IPO companies, as well as guidance and oversight for corporate governance.

Stephen Giblin, board director, is an accomplished leader in the global hospitality, technology and real estate industries with a demonstrated track record of value creation. Juan Pablo Flores, independent director, is an attorney with more than 25 years of legal experience with a strong background in municipal, government, real estate, corporate and general civil law litigation.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $4.35, up 4.35%, on 53,099 volume with 71 trades. The average volume for the last 3 months is 154,183 and the stock's 52-week low/high is $0.769/$7.789.

Recent News


Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Global technology and value-added solutions group Net Element Inc. (NASDAQ: NETE) is launching Blade – an artificial intelligence-based, fully-automated underwriting solution with predictive scoring, a company announcement noted (

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

With an eye on emerging markets, Net Element is pursuing growth opportunities and footholds in a number of industries. The company’s most recent application of its technology is to the cannabis industry, which is paced to hit $591 million and could increase 40 times in the next four years. This rampant growth also creates heightened need for smooth transactions between merchants and consumers. Payment processing and compliance for the cannabis industry has become increasingly complex, and Net Element’s Unified Payments subsidiary is addressing the challenges by offering a compliant, seamlessly integrated payment solution that makes it simple to transact.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $3.98, up 1.79%, on 9,955 volume with 95 trades. The average volume for the last 3 months is 42,985 and the stock's 52-week low/high is $3.75/$10.60.

Recent News


Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings Inc. (OTCQB: GRYN), a full-scope premium cannabis cultivation company targeting the high-end medical and adult-use recreational markets, is moving to purchase over 824 acres of prime pasture in California’s San Diego County with an eye toward planting hemp – the nation’s newest legal crop. Now in escrow, the ranch property will provide Green Hygienics Holdings with room to grow hemp in California’s rapidly expanding cannabis industry, which reaped approximately $2 billion in total sales in 2018, according to Benzinga (

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $1.80, up 23.29%, on 33,726 volume with 53 trades. The average volume for the last 3 months is 20,978 and the stock's 52-week low/high is $0.100/$1.81.

Recent News


Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (ETST) was featured today in the 420 with CNW by CannabisNewsWire. If you were wondering how fast marijuana could become a mainstream substance, the Church of England has just provided further proof that this once heavily stigmatized plant is getting the recognition and acceptance that it deserves. The Church of England has instructed its number crunchers to start making investments in medical marijuana companies.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.78, up 5.41%, on 198,350 volume with 64 trades. The average volume for the last 3 months is 39,000 and the stock's 52-week low/high is $0.30/$2.45.

Recent News


Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today its initial plans and strategy for a national rollout of its SofPulse® targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.


Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.


Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $0.01292, up 29.20%, on 22,050,762 volume with 435 trades. The average volume for the last 3 months is 2,660,871 and the stock's 52-week low/high is $0.008/$0.066.

Recent News


City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

Budd Hutt Inc. ("Budd Hutt" or the "Company"), a private company of which City View Green Holdings Inc. (CSE: CVGR), a company listed on the Canadian Stock Exchange ("CVG" or "City View") holds a 19.9% equity interest, is pleased to announce that it has entered into an agreement to acquire eight pre-license retail cannabis store locations in the Alberta market.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.


Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed the day's trading session at $0.11, even for the day, on 2,000 volume with 2 trades. The average volume for the last 3 months is 218,077 and the stock's 52-week low/high is $0.0949/$0.465.

Recent News


Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers (TSX.V: RIV) (OTC: CNPOF) this morning announced that the company has granted incentive stock options under its stock option plan to certain officers to purchase a total of 1,263,000 subordinate voting shares, each at a price of $3.87. According to the update, subject to TSX Venture Exchange policies, the options are exercisable for a period of five years. To view the full press release, visit:

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $3.75, off by 3.10%, on 131,196 volume with 434 trades. The average volume for the last 3 months is 441,709 and the stock's 52-week low/high is $2.40/$11.82.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). Also today, NetworkNewsWire released a report highlighting the company, which examines the recent news that DehydraTECH(TM) is credited as part of the major appeal of Nuka Enterprises LLC’s 1906 cannabis edibles.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.8508, off by 2.20%, on 20,823 volume with 46 trades. The average volume for the last 3 months is 104,504 and the stock's 52-week low/high is $0.75/$2.43.

Recent News


Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Los Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) today announces it is finalizing negotiations for a series of strategic transactions that could reshape the California cannabis marketplace. Under the terms of the agreements, which are being negotiated and are not final, the Company will gain significant indoor, outdoor and greenhouse cannabis cultivation operations; an existing cannabis retail presence; a team of highly experienced cultivators and managers; and a direct cash infusion from a strategic investment group. Also today, the company was highlighted in a publication from, examining how, since the early 1960’s… or maybe even earlier… people in the U.S. have been growing cannabis/marijuana for personal use and for sale on the black markets. They would set up crop locations in remote areas, or in a clearing in a forest, or in the middle of corn fields. Some even used nets like the military to hide their operations from the air! All of these techniques were eventually foiled by the authorities over time… which caused the ‘outlaw’ cannabis growers to move their operations inside to escape detection.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed the day's trading session at $0.75, off by 11.76%, on 280,413 volume with 164 trades. The average volume for the last 3 months is 62,034 and the stock's 52-week low/high is $0.748/$5.94.

Recent News


Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was highlighted in an article on titled '9 CBD Gifts for Your Friend Who Needs to Chill Out'. The article focuses on cultivation and the significance of high-quality CBD. Inspired by Wildflower's CEO, its CBD+ Cool Stick is a favorite among its consumers. Grown in soil without fertilizers or pesticides and featuring natural elements such as Coconut oil, Beeswax, and peppermint essential oils, the Cool Stick provides instant cooling relief for joint, muscle, and back pain. The product is available for purchase on the company’s website ( To view the full article, visit:

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.459365, off by 6.35%, on 13,257 volume with 19 trades. The average volume for the last 3 months is 23,746 and the stock's 52-week low/high is $0.009/$1.129.

Recent News


Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (FRANKFURT: NXFE) is pleased to announce additional results from its ongoing 2019 shallow vertical diamond drilling program at its flagship Cyclops, nickel/cobalt development project, Indonesia. The drilling is part of a multi-faceted exploration program aimed at confirming historical results and producing a resource estimate in late 2019. Also today, NetworkNewsWire released a report on the company detailing how growth in demand for batteries is pushing up nickel production around the world.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated ( “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.104, off by 5.49%, on 16,500 volume with 2 trades. The average volume for the last 3 months is 23,629 and the stock's 52-week low/high is $0.0701/$0.3588.

Recent News


Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade Inc. (OTC:SGMD) announces the availability of an audio press release titled, “Demand for CBD Places Power in Hands of Extraction Providers.” To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include:;; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.


CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.032, off by 20.99%, on 2,909,817 volume with 218 trades. The average volume for the last 3 months is 1,646,225 and the stock's 52-week low/high is $0.0225/$0.1975.

Recent News


Cool Events Inc. (RNWR)

The QualityStocks Daily Newsletter would like to spotlight Cool Events Inc. (RNWR).

Cool Events Inc. (RNWR) offers an array of unique, experiential running and obstacle events that attract thousands of participants sharing a passion for running and helping others. The company produced over 120 events in 2018 under the banner of five successful brands and has already lined up venues for 2019.

Cool Events offers the following trademarked events throughout the nation, with each dedicated to raising funds for important charities: Blacklight Run, the largest glow powder run in the world; Bubble Run, the largest daytime 5K run in the country; Foam Glow, The largest nighttime glow run in the country and the world’s only glowing foam run; Blacklight Slide, the first and only close to five story high Glow-N-Dark water slide with neon glowing water; and Terrain Race, the nation’s fastest growing and industry leading obstacle course race for all ages and athletic abilities.

Cool Events dedicates each of its trademarked runs and events to childhood cancer awareness, making sure this critically important issue is spread throughout the nation one runner, one race at a time. Since its first event in August 2013, the company has donated more than $1 million to Phoenix Children’s Hospital/Children’s Miracle Network and hundreds of thousands more to other charity partners such as Ronald McDonald House Charities of New Mexico, Make-a-Wish Foundation, Adoption Awareness, Special Olympics Massachusetts, St. Jude Children’s Research Hospital, Kendra’s Kisses, Boys and Girls Club and many more over the years.

Cool Events brings a seasoned management team with 35 years of combined experience in operating experiential events including obstacle course races, running races, experiential family events and other competitive events. The Cool Events team also offers consulting, marketing and development for outside events. The company’s in-house marketing agency can handle all brand awareness for event strategy, bringing an event’s vision and goals to life.

Cool Events Inc. (RNWR), closed the day's trading session at $0.085, up 63.46%, on 6,882 volume with 2 trades. The average volume for the last 3 months is 7,940 and the stock's 52-week low/high is $0.002/$0.231.

Recent News


Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.


The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.


Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.


Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.022, even for the day, on 250 volume. The average volume for the last 3 months is 19 and the stock's 52-week low/high is $0.009/$0.029.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.